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2:00 
~-'4"- I  Low Level Physical Training Improves Oxygen Peak 
Consumption in Patients With Congestive Heart 
Failure Despite Long Term Beta Adrenergic 
Blockade by Enhancing Vascular Conductance and 
Growth 
Laura Demopeufos, Marco Testa. Gemrdo Zullo, Marco Gentilucci, 
Margaret Jones, Michael Yeh, Pugazhendhi Vijdyaraman, Patrick Moore, 
Thlerry H. LeJemtel. Albert Einstein College of Medicine, Bronx, Ne~ York 
In the absence of beta adranergic blockade (BAG), 12 weeks of low level 
physical training (PT) at a workload corresponding to _<50% of peak oxy- 
gen consumption (VO2) has been shown to increase peak VO2 in patients 
with congestive heart failure (CHF). In normal subjects, BAB aten uates the 
benefits of PT by preventing cardiac and skeletal muscle adaptations that 
contribute Io increasing maximum VO2. Accordingly, 10 patient~ with CHF on 
long term therapy with ACE tnhibifors, digexin, loop diuretics, : . BAB (rest 
and peak heart rates 64/rain and t18/min) unde,,went 12 weeks of low level 
PT. Peak VO2 (mltmin/kg) and calf peak hypemmic response by ptethys- 
mograpby (CPHR, ml/min/100 ml) were measured at baseline (BL) and after 
12 weeks of low level PT. Gene expression of vascular endothelial growth 
factor (VEGF) was quantified by competitive PCR or~ reverse transcnbed 
mRNA obtained from vestus latemlis muscle biopsies at BL and 12 weeks. 
VEGF was normalized to glyceraldohyde-3-phesphalq dehydrugenase, and 
expressed a.~ a fold increase from BL. 
Peak VO2 CPHR VEGF 
BL 13.8 18.4 - 
12 weeks 17.4" 26.3* 3--7 
• p < 0.0=; vs BL 
Conclusion: In patients with CHF on long term BAB, low level PT sub- 
stantially increases 1) peak VO2. 2) CPHR and gene expression of VEGR 
Enhanced vasodilatory capacity and angiogenesi~, in the skeletal muscle 
beds appear to mediate the improvement inpeak VO2 induced by low level 
PT in these patients. 
2:15 
-5~ Amledarone Produces Effects Similar to ~-Blockers 
in CHF 
Barry M. Massie, Susan G. Fisher, Martha Radford, Ross D. Fletcher, 
Steven N. Singh, for the CHF-STAT Investigators. VAMC, andUniv, of 
California, San Francisco, CA 
Although amiodamne (AMIO) did not reduce total or sudden death mortality 
in the recently published CHF-STAT •al, them was a favorable trend (p = 
0.07) in patients with a non-lschemic etiology (NI) of CHR Evidence of greater 
e~icacy in NI patients has also been noted with/~.btockers in CIBtS and other 
smaller studies, and the most impressive results have been improvement in
LV function and prevention of endpoints related to progressive CHF rather 
than sudden death. Since AMIO has/~.blocking activity, the present analyses 
were undertaken to determine whether it produces similar functional and 
endpoint changes, and whether these effects occur priman'ly in Nt patients. 
in CHF-STAT, 674 patients with NYHA class 2-4 CHF (71% ischemic, 29% 
NI) and LV EF < 40% were randomized Io AMIO or placebo. At 6 rues, them 
was a greater increase in LV EF on AMIO (8.1 • 10.2 vs 2.6 ± 7.8 EF units, 
p < 0.001), but this was significantly greater in NI than CAD patients (12.3 ± 
11 vs 6,6 ± 2.1 units). The change in EF was inversely related to change in 
heart rate. An improvement inEF >_ 5% was associated with an improvement 
in survival in the N! group (p < 0.001 ), but not in CAD patients, In NI patients, 
AMIO was associated with reductions in hospitalizations for CHF (RR 0.56, 
[0,31-1.02], p = 0.06), CHF deaths plus CHF hospitalizations (RR 0.49 
[0.28-0.85], p = 0.01), and cardiac deaths plus CHF hospitalizations (RR 
0.56 [0,36-0.87], p = 0.01). None of these endpolnts was affected in CAD 
patlanta (RR 0.93-0.95). These results demonstrate that AMIO increases LV 
EF, particularly in NI caKllomyopathy. These changes am associated with 
improvement in clinical outcomes, especially those related to progressive 
CHF, in NI patients but not in those with CAD. This profile of effects is very 
similar to those observed with p-blockers in CHF. 
2:30 
~-~-~ Eflscts of Carvedilol on Cardiovascular 
Hospitalizations in Patients With Chronic Heart 
Failure 
Michael B. Fowler, E. Michael Gilbert, Jay N. Cohn, Michael A. Bristow, 
Wilson S. Colucoi, Nell H. Shusterman, Milton Packer for the Carvedilol 
Heart Failure Study Group. Stanford University, Stanford, CA 
Carvedilol (C), a nonselective /~-adrenergic blocking drug with vasodilat- 
ing and antioxidant effects was recently compared to placebo (P) in a trial 
program consisting of 4 muiticenter, andomized ouble-blind studie ~- run 
concurrently across the U.S. 1094 patients with NYHA II-IV heart failure 
(and LVEF < 35%) were randomized to receive treatment for 6-12 months. 
To evaluate the effect of C on hespifal admissions, data on art hospitatiza- 
tions were prospectively obtained throughout the study period, and analyzed 
according to protocol for patients who completed 2 months of maintenance 
therapy (588 p~ents on C, 334 on P). 
Carvediiol therapy was associated with a 38%° (95% CI: 0.149, 0.542; p = 
0.003, Cochran-ManteI.Haeeszel) reduction in risk of hospitalization (for all 
cardiovascular mesons). Hospitalization for heart failure was reduced by 47% 
(95%, Ch 0.135, 0.673; p = 0.011). Hospitalization for MI occurred in 0.3% uf 
patients randomized to C compared to 1.2% in the P group (p = 0.067). 
A decrease in the duration of the hospital stay by 1.3 days (95% CI; 0.3, 2.2; 
p = 0.009, analysis of variance) was also seen in the patients treated with C. No 
differences were observed for eardiovescular hospitalizations (CV) or hospi- 
talizations for CHF among the subgroup analyses for 1oasetine characteristics 
of age, sex, race, NYHA class, LVEF, history of MI and etiology of disease. 
In conclusio=i, earvedilot provides a substantial clinical benefit o patients 
with class II-IV heart failure by reducing the dsk of all CV hospitalizations by 
38% and hospitalizations for CHF by 473'0. The dumtlon of hospital stay was 
also shorter in patients receiving eawediloL The reduction in hospitalizations 
observed Is concordant wittt he moffality t~enefit reported in patients treated 
with ca~edHol. 
2:45 
~"5"~ Effect of Carvedilol in Severe Chronic Heart Failure 
Jay N. Cohn, Michael B. Fowler, Michael A. Bristow, Wilson S. Coluccl, E. 
Michael Gilbe¢ V'dhal Kmal, Stavan K. Kmeger, Thieny LeJemtal, Kenneth 
A. Namham, Milton Packer for the Carvedilcl Heart Failure Study Group. 
University of Minnesota, Minneapolis, MN 
Carvedilol (C), a/~.blocker with vesndilaling properties via ~l-blockade, was 
evaluated in patients with severn chronio heart faitum (CHF) [ejection fraction 
(EF) < 0.35, NYHA III/IVJ in a doubts-blind, placebo-controlled trial of 6 
months duration. The protocol was stopped eady upon recommendation of
the Data and Safety Monitoring Board to terminate Phase lit clinical •als 
in light of a survival advantage of C. Ooo-hundred live of a planned 140 
patients on standard therapy (diuretics, digoxin, and ACE-l) enJ unable to 
walk 350 rn in 6 rain were randomized to receive maximally tolerated C (n = 
70) up to 25 mg bid or placebo (P; n = 35). Parameters evaluated included 
change in quality of life (Minnesota Living with Heart Failure Questionnaire), 
patiant/physiclan global assessment and EF. Analyses (at end-paint) were 
limited to 40 patients on C and 21 on P, doe to truncation of the study. 
Results: p~Jents receiving C had a greater increase in EF at 6 months 
compared to P (+0.09 vs +0.02; p = 0.004). Ctfnical benofit was evidenced 
by improvement inthe global assessment by patients in 88% on C vs 67% 
on P (p = 0.032), and by physicians in 83%0 vs 52% (p = 0.023). Only 3% of 
pat ie~ic ians  reported worsening on C, whereas 19% patients and 15% 
physicians reported worsened CHF on R Two deaths (2.9%) occurred on C 
and two (5.7%) on R Several other measures of efficacy favored C without 
roaching statistical sk~::~noe, including change in quality of life scorn (+12 
C; +9 P), 6-rain walk distance (299.9 m on C, 278.3 m on P), improvement in
NYHA Class (23% C vs 1 9% P). Hospitalizations for worsening CHF occurred 
in 7.5% of patients on C, and 4.8% on P. 
Conclusion: The addition of ¢an~dilol to diuretics, d'rgoxin and ACE-I 
therapy in patients with severe CHF results in an improvement in EF and 
reduced risk of clinical deterioration. These data are concorda~ with the 
hamedynamic and clinical be,nef'~ observed in patients with less severn 
CHF treated with can/an31ot. 
3:00 
~- -~ '~ C arvedllol Reduces Left Ventdcular Volumes in 
Patients With Heart Failure of Ischemic Etiology 
Robert Doughty, Gillian Whalley, Stephen MacMahen, Norman Sharpe on 
behalf of the Australia-Now Zealand Heart Failure Research Collaborative 
Group. Unfversity of Auckland School of Medicine, Aucktand. New Zealand 
Bata-blocker therapy has been shown to increase left ventdoutar ejection 
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fraction (LVEF) in patients with heart failure of ischemic and non-ischemic 
etiology. To investigate the mechanism oi this tmpmvemer~t LVvolumes were 
assessed in a subgroup of 123 participants from the ANZ Head Failure 
Research Collaborative Group Trial. In this trial, patients with chronic sta- 
ble heart failure of ischemic etiology on standard treatment including ACE 
inhibitor were randomised to treatment with ce'Nedilol (25-50 mg daily) or 
placebo. At baseline and after 6 months treatment LV end-diastolic and end- 
systolic volume indices (LVEOVI and LVESVI) were estimated from apical 4 
and 2 chamber echocardiographic views (modified S~mpson's rule). After 6 
months resting head rate was reduced by 7 bpm (2P < 0.01). Results are 
given below as change from baseline to 6 months: 
Treatment  LVEDVI myrrh" LVESVI ml/m 2 LVEF % 
Placebo (60) +4.35 :E 2 +4.0 -I- 1.8 -0.S ~: 0.9 
C.,arvedflol {63) -3.7 ~ 1.7" -6.2 ~- 1.a t 4.3 :E 0.9 I" 
SVI-slmke volume index. Values represent mean ± SEM. *2P < 0.05; t2P < 0.01 (all for 
¢ante@ltol vemus placebo). 
Conclusion: these results provide slrong evidence that carvedilol reduces 
LV volumes and increases LVEF in patients with heart failure of ischemio 
etiology, These results are consistent with an intrinsic improvement in LV 
function. 
3:15 
['7~'-'6-'( Improvement After in Dilated Metoprolol Idiopathic 
Cardiomyopathy Is Predicted by.Baseline Systolic 
Blood Pressure and Change in Heart Rate 
Finn Waagstaln, Kad Swedberg I Ake Hjalmarson for the f, ilDC Tdal Study 
Group. Sahlgrenska, University Hospitals, Geteborg, Sweden.; 10stra 
University HospItals, GOteborg, Sweden. 
Initial reports on/z-blockerS in idiopathic dilated cardiomyopathy (IDC) sug- 
gested beneficial effect of/~-blockers in endstage IDC with tachycardia. 
Concern has been raised whether/]:blockers affect less sick patients without 
tachycerdia nd long duration of disease. 
Baseline variables from 383 patients with IDC with ejection fraction (EF) < 
0.40 in a randomized placebo-controlled t al were analyzed with regard to 
their predictivity for improvement ofEF by >_7 units by univariats and step- 
wise multivariate analysis. The following variables were tested: age, sex, 
smoking, concomitant treatment with digitalis and ACE-inhibitors, duration of 
disease, family histoPj of IDC, heart rate (HR), absolute and percent change 
in HR, systolic blood pressure (SBP), stroke work index, EF and exercise 
time. 
>p-value p-value 
(univarlate) (multivariate) 
Duration of disease 0.15 NS 
Smoker 0.06 NS 
Baseline HR < 0.05 NS 
Z~HR {beats/min) ~: 0.05 < 0.05 
&HR (%) < 0.05 NS 
SBP < 0.06 < 0.05 
Marked reduction of HR after metoproicl predicts improvement and em- 
phasize the importance of aiming at maximal reduction in HR by titration of 
metoprolol in the individual case. Duration of disease, NYHA class and EF 
at baseline were not found to be independent predictors of improvement. 
Hypotension may be an obstacle to improvement. 
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2:00 
~ ' ~  Late Potentials Are Related to the Degree and 
Extent of Viable Myocardlum After Acute Myocardial 
Infarction 
Mada-Aurera Morales, Antonio Fazil Ezio-Mana Ferdeghini, 
Maro~llo Piecenti, Leandro Chiedil Cello Gremigni I Gualtiero Paloal, 
Rossano Vergassota 1, Antonio UAbbate. CNR Clinical Physiology Institute 
Rorence and Pisa, Italy; 1 Cardiology Department, SM Annunzieta Hospital, 
Florence, Italy 
Eady after acute myocardial infarction (AMI) residual viability can be detected 
by 2-0 echocardiography during low-dose dobutamine (DOB) infusion. Aim 
of this study was to evaluate the relationahip between signal averaged ECG 
(SAE) and the amOunt of viable myocardial tissue in patients with recent MI. 
F0dy-eight pts, 37 males, mean age 60 + 8 years, underwent a DOS-echo 
test 14 =1:3 days after ML SAE was recorded immediately before the teat. An 
abnormal SAE was defined as having two of the following: fQRS >_ 115 ms, 
LAS40 >__ 38 ms, RMS40 < 25 p.V (40 Hz Bufterwodh filter; noise < 0.7/zV). 
DOB was intravenous infused at 5 and 10 mg/Kg/mln, each dose dudng 5'. 
Optimal echr,, reoordins~ were obtained in 42/48 pts. Quantitative analysis 
of the LV, divided in 24 segments, was performed on digitized images and 
% area change (%AC) from peak diastolic to peak syatolf¢ area calculated 
by centedine "fixed" system, Of 1008 segments, 208 were judged asynergic 
(%AC < 30% at baseline); a segment was considered viable when DOB 
infusion increased %AC by >__ 35% from basal values. Twenty pts showed 
viable rnyocardlum, Group I (%AC from 21 ~: 7 to 42 ± 10%); in 22 pts, 
Group ti, %AC was unchanged (24.4- 7 to 28 ± 9%). The two groups were 
comparable for type, site, extension of MI, basal EF, thrombolytic therapy and 
time of recording from MI. Late potentials were detected in 17 Group I lOtS 
and in only one of Group II pts (p < 0,001). In Group 1% AC increase dudng 
OOS x number of viable segments was positively eorrelated with IQRS and 
LAS40 and negatively with RMS40 (r = 0.64 p < 0.005, r = 0.69 p < 0.001 
and r = -0,57 p < 0.05, respectively). Thus, early after MI viable myocardial 
tissue can represent the eleotrophysiolo~ic substrate for late potentials. SAE 
parameters are significantly related to beth the extension and degree of 
OOB-induced improvement incontra~lity of asynergic areas. 
2:15 
~ Normal and Abnormal Findings of Signal Averaged 
Electrocardiograph in Survivors Of Acute Myocardial 
Infarction With and Without Follow-Up Events: 
Wavelet Decomposition vs "nme~Domain Analysis 
Katadna Hnatko~a, Anne Staunton, A. John Carom, Marek Malik. St. 
George's Hospital Medical School, London, England 
Simple spectral analysis of signal averaged electrocardiograms (SAECG) 
has been the subject of numerous tudies. However, the approaches reported 
so far appear infer/or to the gold-standard time-domain (TO) analysis. At the 
same time, the limitations of the time-domain analysis are well known and 
suggest that more complex spectral analysis of SAECG wifi be of clinical 
importance. One of the possibilities for a more complex spectral analysis of 
SAECG is the so called wavelet decomposition 0ND) which is a time-scale 
technique suitable for the detection small transient signals even if they are 
superimposed with large waves. 
In this study, tl~e wavelet analysis of SAECG was applied to 85 normal 
healthy volunteers and to 551 survivors of acute myocardial infarction. Four 
parameters were extracted from WD of SAECG: wavelet extracted QRS 
length (WCL), local maxima count 0NMC), surface area 0NSA), and relative 
length of the decomposition (WRL). The standard time domain indices were 
obtained at bi-direotional four-pole Buttsrwodh filter settings of 40-250 Hz. 
Normal limits of each the WD and TD indices were dedved from the 
population of healthy volunteers. The high 95-percentile (that is the cut-point 
for which 95% of normal population had lower values of the index) was used 
for tQRS, I.AS, WCL, WMC, and WSA parameterS. The low 95-percentile 
was used for FIMS and WRL parameters, The following triplets of indices 
were used: TD (time domain indices: t('1RS, RMS, I.AS), WD1 0ND indices: 
WCL, WMC, WSA), and WD2 (WD indices: WMC, WSA, WRL) and with each 
triplet, a SAECG recording was considered abnormal if at least 2 indices were 
outside the normal limits, 
These categorical cdfeda were used to distinguished infarction survivors 
with and without clinical events dudng 1-year fallow-up: 29 cases of cardiac 
death (CM), 15 of sudden death (SD), 14 of non-sudden death (NSD), and 19 
cases of spontaneous ustained verdricular tachycardia (VT). Fisher exact 
test was used to evaluate the association of abnormal SAECGs with these 
end-points. The three SAECG diagnostic possibilities led to the following 
associations (AE = arrhythmlc events = SD + VT):- 
CM AE SD NSD VT 
TD 0.11 0.03 0.25 0.28 0.01 
WOl 0.13 3.81 x 10 -3 0.07 0.57 1.11 x 10 -3 
WD2 0.19 7.7 x 10 -3 0.21 0.58 7.9 x 10 -4 
Thus compared to conventional time domain analysis, the abnormalities 
in wavelet decomposition of SAECG were more strongly associated with 
follow-up events after acute myocandial infarction, 
